X-129575158-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000276.4(OCRL):c.1621C>T(p.Arg541*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000276.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
OCRL | NM_000276.4 | c.1621C>T | p.Arg541* | stop_gained | Exon 16 of 24 | ENST00000371113.9 | NP_000267.2 | |
OCRL | NM_001318784.2 | c.1624C>T | p.Arg542* | stop_gained | Exon 16 of 24 | NP_001305713.1 | ||
OCRL | NM_001587.4 | c.1621C>T | p.Arg541* | stop_gained | Exon 16 of 23 | NP_001578.2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome Cov.: 27
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Lowe syndrome Pathogenic:4
This nonsense variant is categorized as deleterious according to ACMG guidelines (PMID:18414213) and was found once in our laboratory maternally inherieted in a 2-year-old male with global delays, sensorineural hearing loss, hypotonia, dysmorphisms, short stature, septo-optic dysplasia, bilateral cateracts, brain cyst, nephrocalcinosis/hypercalcemia, craniosynostosis, delayed bone age, undscended testes -
For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 521093). This premature translational stop signal has been observed in individual(s) with clinical features of Lowe syndrome (PMID: 25326635, 25480730). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg541*) in the OCRL gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in OCRL are known to be pathogenic (PMID: 19390221, 21031565, 22381590). -
- -
Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant.It is not observed in the gnomAD v2.1.1 dataset. The variant has been reported at least twice as pathogenic/likely pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000521093, 3billion dataset). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. -
Nephrolithiasis/nephrocalcinosis Pathogenic:1
The c.1621C>T (p.R541*) alteration, located in exon 16 of the OCRL gene, consists of a C to T substitution at nucleotide position 1621. This changes the amino acid from an arginine (R) to a stop codon at amino acid position 541. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been reported in multiple individuals with clinical features consistent with Lowe syndrome (Hichri, 2011; Recker, 2015; Sinha, 2022; Sakakibara, 2022). Based on the available evidence, this alteration is classified as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at